Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $71.2 in the last session, up 1.27% from day before closing price of $70.31. In other words, the price has increased by $1.27 from its previous closing price. On the day, 2.9 million shares were traded. HALO stock price reached its highest trading level at $71.645 during the session, while it also had its lowest trading level at $69.18.
Ratios:
We take a closer look at HALO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.90. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 1.59.
On October 14, 2025, Leerink Partners Upgraded its rating to Market Perform which previously was Underperform but kept the price unchanged to $70.
Morgan Stanley Upgraded its Equal-Weight to Overweight on August 06, 2025, while the target price for the stock was maintained at $75.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 ’26 when BERNADETTE CONNAUGHTON bought 2,000 shares for $70.31 per share.
Caudill Cortney sold 4,263 shares of HALO for $277,905 on Nov 01 ’25. The SVP, CHIEF OPERATING OFFICER now owns 12,737 shares after completing the transaction at $65.19 per share. On Dec 01 ’25, another insider, Connaughton Bernadette, who serves as the Director of the company, sold 829 shares for $71.60 each. As a result, the insider received 59,356 and left with 42,123 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8372905984 and an Enterprise Value of 9209801728. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.97, and their Forward P/E ratio for the next fiscal year is 8.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.74 while its Price-to-Book (P/B) ratio in mrq is 16.61. Its current Enterprise Value per Revenue stands at 7.41 whereas that against EBITDA is 11.324.
Stock Price History:
The Beta on a monthly basis for HALO is 0.96, which has changed by 0.37351048 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $79.50, while it has fallen to a 52-week low of $47.50. The 50-Day Moving Average of the stock is 5.57%, while the 200-Day Moving Average is calculated to be 11.77%.
Shares Statistics:
According to the various share statistics, HALO traded on average about 2.19M shares per day over the past 3-months and 1383620 shares per day over the past 10 days. A total of 117.52M shares are outstanding, with a floating share count of 116.27M. Insiders hold about 1.13% of the company’s shares, while institutions hold 103.05% stake in the company. Shares short for HALO as of 1765756800 were 12500858 with a Short Ratio of 5.72, compared to 1763078400 on 12479411. Therefore, it implies a Short% of Shares Outstanding of 12500858 and a Short% of Float of 14.81.
Earnings Estimates
The performance of Halozyme Therapeutics Inc (HALO) in the stock market is under the watchful eye of 5.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $1.81, with high estimates of $1.99 and low estimates of $1.57.
Analysts are recommending an EPS of between $6.39 and $6.18 for the fiscal current year, implying an average EPS of $6.25. EPS for the following year is $8.13, with 4.0 analysts recommending between $9.02 and $7.18.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $394.63M. It ranges from a high estimate of $417M to a low estimate of $373.1M. As of. The current estimate, Halozyme Therapeutics Inc’s year-ago sales were $298.01MFor the next quarter, 7 analysts are estimating revenue of $370.97M. There is a high estimate of $399.07M for the next quarter, whereas the lowest estimate is $352M.
A total of 8 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.36B, while the lowest revenue estimate was $1.32B, resulting in an average revenue estimate of $1.34B. In the same quarter a year ago, actual revenue was $1.02BBased on 7 analysts’ estimates, the company’s revenue will be $1.68B in the next fiscal year. The high estimate is $1.79B and the low estimate is $1.58B.
